BOSTON--(BUSINESS WIRE)--Click to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that two important upcoming medical meetings have accepted its abstracts relating to the role of transient receptor potential ion channel activators to treat and prevent muscle cramping and spasms.
Help employers find you! Check out all the jobs and post your resume.
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that two important upcoming medical meetings have accepted its abstracts relating to the role of transient receptor potential ion channel activators to treat and prevent muscle cramping and spasms.
Help employers find you! Check out all the jobs and post your resume.
